This inventor holds 13 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignees: Alkermes Pharma Ireland Limited, Alkermes, Inc.. Active years: 2013-2025.
Company Filing History:
Years Active: 2013-2025
Title: Mark Todtenkopf: Innovator in Antipsychotic Treatment
Introduction
Mark Todtenkopf is a notable inventor based in Franklin, MA (US). He has made significant contributions to the field of pharmacology, particularly in the treatment of weight gain associated with antipsychotic medications. With a total of 13 patents to his name, Todtenkopf's work is recognized for its innovative approaches to addressing complex medical issues.
Latest Patents
Among his latest patents, Todtenkopf has developed methods for treating antipsychotic-induced weight gain. This invention relates to the discovery of a novel opioid modulator that effectively reduces pharmacologically induced weight gain associated with atypical antipsychotic use. The methods provided aim to suppress food intake and reduce ghrelin levels in patients taking atypical antipsychotic medications.
Career Highlights
Throughout his career, Mark Todtenkopf has worked with prominent companies in the pharmaceutical industry, including Alkermes Pharma Ireland Limited and Alkermes, Inc. His expertise in pharmacology and innovative thinking has led to advancements in treatment options for patients.
Collaborations
Todtenkopf has collaborated with several professionals in his field, including Daniel R Deaver and Derrick Arnelle. These collaborations have contributed to the development of his patents and the advancement of treatment methodologies.
Conclusion
Mark Todtenkopf's contributions to the field of pharmacology, particularly in treating antipsychotic-induced weight gain, highlight his innovative spirit and dedication to improving patient outcomes. His work continues to influence the medical community and offers hope for those affected by the side effects of antipsychotic medications.